PDGFRB and neoplasm: The recent availability of potent and specific tyrosin kinases inhibitors such as imatinib mesylate, which was developed as an ATP competitive inhibitor of ABL tyrosine [14] that, at concentrations required for inhibition of Bcr-Abl, also inhibits PDGFR and c-Kit [15], has revived the interest on the PDGFR as potential therapeutic target for several neoplasms, including solid tumors [16,17].